KZIA Stock Alert: Kazia Continues Its Surge on Thursday With 51% Gains
- Kazia Therapeutics (NASDAQ: KZIA ) stock is continuing to rally on Thursday after the company reported positive alongside clinical trial data yesterday. The Kazia Therapeutics clinical trial covered the company's paxalisib as a treatment of glioblastoma.
- 07/11/2024
|
There's a very short window to bet against the dollar, says Goldman Sachs.
- Should inflation behave as economists expect, there may be a window — a very brief window — to bet against the U.S. dollar DXY. That's the conclusion of Karen Reichgott Fishman, senior currency strategist at Goldman Sachs.
- 07/11/2024
|
Kazia Therapeutics Shares Are Jumping Today: Successful Study For Brain Cancer Treatment
- Kazia Therapeutics Limited KZIA released results on Wednesday from the GBM-AGILE Phase 2/3 study that included an evaluation of paxalisib versus standard of care (SOC) for patients with glioblastoma, a type of brain cancer.
- 07/10/2024
|
Why Is Kazia Therapeutics (KZIA) Stock Up 300% Today?
- Kazia Therapeutics (NASDAQ: KZIA ) stock is soaring higher on Wednesday after the oncology-focused biotechnology company provided results from a Phase II/III clinical trial. These results concern the effectiveness of paxalisib as a treatment of glioblastoma versus the standard of care (SOC).
- 07/10/2024
|
Kazia Therapeutics Announces Phase II/III Clinical Trial Results for Paxalisib in Glioblastoma
- GBM AGILE trial data shows clinically meaningful improvement in a prespecified secondary analysis for overall survival in paxalisib-treated, newly diagnosed unmethylated patients with glioblastoma SYDNEY , July 10, 2024 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, is pleased to announce results from GBM-AGILE, a phase II/III study that included an evaluation of paxalisib versus standard of care (SOC) for patients with glioblastoma (NCT03522298), a life-threatening brain cancer, where there is an urgent unmet need for new therapeutics. GBM AGILE STUDY GBM AGILE is an adaptive phase II/III global trial sponsored by the Global Coalition for Adaptive Research (GCAR), a nonprofit organization comprised of some of the world's foremost clinical, translational, and basic science researchers, from institutions such as Memorial Sloan Kettering Cancer Center and Dana-Farber Cancer Institute.
- 07/10/2024
|
KAZIA ANNOUNCES UPCOMING DIPG DATA PRESENTATIONS AT ISPNO AND PUBLICATION IN EUROPEAN JOURNAL OF CANCER
- SYDNEY , June 27, 2024 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), a biotechnology company specialising in oncology, is pleased to announce the presentation of new data from its lead program, paxalisib, at the upcoming 21st International Symposium on Pediatric Neuro-Oncology (ISPNO 2024) June 29 – July 2, 2024, in Philadelphia, PA. Kazia concurrently announces publication of an article in European Journal of Cancer highlighting the need for evaluating mutation-specific, CNS penetrant, inhibitors to treat pediatric patients with Diffuse Midline Glioma (DMG).
- 06/27/2024
|
Kazia Granted 180-Day Extension by Nasdaq to Meet the Minimum Bid Price Requirement
- SYDNEY , May 23, 2024 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) (Kazia or the company) received a letter on May 22, 2024 from Nasdaq notifying the Company that, while the Company has not regained compliance with the Minimum Bid Price Requirement, Nasdaq has determined that the Company is eligible for an additional 180 calendar day period, or until November 18, 2024 (the "Second Compliance Period"), to regain compliance with the Minimum Bid Price Requirement. As previously disclosed, on November 20, 2023, Kazia Therapeutics Limited (the "Company") received a deficiency notification from the Listing Qualifications Staff of the Nasdaq Stock Market LLC ("Nasdaq"), notifying the Company that it was not in compliance with the minimum bid price requirement as set forth in Nasdaq Listing Rule 5550(a)(2) (the "Minimum Bid Price Requirement").
- 05/23/2024
|
KAZIA REPORTS SUCCESSFUL STAGE 1 COMPLETION OF THE EVT801 PHASE 1 CLINICAL TRIAL IN ADVANCED CANCER PATIENTS
- SYDNEY , May 1, 2024 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), a biotechnology company specialising in oncology, is pleased to announce that the Safety Review Team (SRT) of the EVT801 Phase 1 clinical trial has concluded that the primary and secondary objectives of stage 1 of the trial have successfully been met. Consisting of the trial's lead investigators, independent medical monitor, and key members from Kazia Therapeutics, the SRT has reviewed all preliminary (non-final) safety and pharmacokinetic (PK) data, and unanimously agreed that the maximal tolerated dose (MTD) has been reached at 500mg twice a day (BID).
- 05/01/2024
|
Kazia Therapeutics licenses paxalisib to Sovargen for intractable seizures in rare central nervous system diseases
- SYDNEY , March 21, 2024 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), a biotechnology company specialising in oncology, is pleased to announce that it has entered into an exclusive licensing agreement with Sovargen Co., Ltd, a biotechnology company specializing in central nervous system (CNS) diseases, to develop, manufacture and commercialise paxalisib as a potential treatment of intractable epilepsy in focal cortical dysplasia type 2 (FCD T2) and tuberous sclerosis complex (TSC) disease. The underlying cause of FCD T2 and TSC can be traced back to somatic mutations in the PI3K/Akt/mTOR pathway or mutations in the TSC1 or TSC2 genes, which lead to the overactivation of the mTOR pathway.
- 03/21/2024
|
Kazia announces presentation of new data at AACR Annual Meeting
- SYDNEY, March 13, 2024 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), a biotechnology company specialising in oncology, is pleased to announce the presentation of new data for both its pipeline molecules, paxalisib and EVT801, at the upcoming Annual Meeting of the American Association of Cancer Research (AACR) in San Diego, California, from 5-10 April 2024. There will be three presentations in total at AACR, including data from the phase 1 study of EVT801 in advanced solid cancers.
- 03/13/2024
|
Kazia Therapeutics Reports Early Conclusion of Clinical Trial After Reaching Primary Endpoint
- Paxalisib plus Radiotherapy Data Shows Promise for Treating Patients with PI3K Pathway Mutation Brain Metastases SYDNEY , Feb. 21, 2024 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), a biotechnology company specializing in oncology, today announced the early conclusion based on positive safety and promising clinical response findings observed to date of an important two-part Phase I trial. This investigator-initiated trial evaluated the use of paxalisib (an oral PI3K/mTOR dual inhibitor) with radiation therapy for the treatment of patients with PI3K pathway mutation brain metastases from solid tumors.
- 02/21/2024
|
KAZIA CONTINUES BOARD RENEWAL WITH TWO NEW APPOINTMENTS
- SYDNEY , Jan. 18, 2024 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, is pleased to announce the appointment of pharma industry executive, Mr. Robert Apple to Kazia's Board of the Directors (the "Board") as a Non-Executive Director.
- 01/18/2024
|
Kazia Therapeutics Announces Closing of $2 Million Registered Direct Offering
- SYDNEY , Dec. 5, 2023 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused drug development company, today announced the closing of its previously announced purchase and sale of up to an aggregate of 4,444,445 of the Company's American Depositary Shares ("ADSs") (or ADS equivalents in lieu thereof), each ADS representing ten (10) ordinary shares of the Company, at a purchase price of $0.45 per ADS (or ADS equivalent in lieu thereof), in a registered direct offering. The Company also issued in a concurrent private placement unregistered warrants to purchase up to an aggregate of 4,444,445 ADSs.
- 12/05/2023
|
Kazia Therapeutics Announces $2 Million Registered Direct Offering
- SYDNEY , Dec. 1, 2023 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused drug development company, today announced that it has entered into a definitive agreement for the purchase and sale of up to an aggregate of 4,444,445 of the Company's American Depositary Shares ("ADSs") (or ADS equivalents in lieu thereof), each ADS representing ten (10) ordinary shares of the Company, at a purchase price of $0.45 per ADS (or ADS equivalent in lieu thereof), in a registered direct offering. The Company has also agreed to issue in a concurrent private placement unregistered warrants to purchase up to an aggregate of 4,444,445 ADSs.
- 12/01/2023
|
KAZIA ANNOUNCES NON-BINDING LETTER OF INTENT FOR THE PROPOSED GRANTING OF RIGHTS TO DEVELOP AND COMMERCIALIZE PAXALISIB OUTSIDE OF ONCOLOGY
- SYDNEY , Nov. 29, 2023 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, is pleased to announce that it has signed a non-binding Letter of Intent (LOI) with an undisclosed biotechnology company for the license of worldwide rights, other than mainland China, Hong Kong, Macao and Taiwan, to develop and commercialize pharmaceutical product containing paxalisib in an indication outside of cancer. Mutual due diligence has been completed and each company has agreed to move forward to negotiate and use their best efforts to agree to the terms of a definitive agreement.
- 11/29/2023
|
KAZIA PROVIDES OVERVIEW OF PAXALISIB RELATED PRESENTATIONS FROM THE SOCIETY OF NEURO-ONCOLOGY 2023 ANNUAL MEETING
- SYDNEY , Nov. 21, 2023 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, is pleased to provide key highlights of the clinical and preclinical paxalisib related presentations given by key thought leaders at the Society of Neuro-Oncology 2023 Annual Meeting. "The 2023 SNO Annual Meeting was another successful event with the latest advances in clinical trials, diagnosis and treatment of pediatric and adult patients with CNS malignancies," stated Dr. John Friend, CEO Kazia.
- 11/21/2023
|
KAZIA ANNOUNCES RECEIPT OF NASDAQ MINIMUM BID NOTIFICATION
- SYDNEY , Nov. 20, 2023 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) (Kazia or the company) received a deficiency notification from the Listing Qualifications Staff of the Nasdaq Stock Market LLC (Nasdaq), dated November 20, 2023, notifying the company that it is not in compliance with the minimum bid price requirement set forth in the Nasdaq Capital Market's rules for continued listing (the Notice). The deficiency notification has no immediate impact on the company's operations or listing.
- 11/20/2023
|
KAZIA ANNOUNCES THE RELEASE OF PNOC022 CLINICAL STUDY ABSTRACT HIGHLIGHTING PAXALISIB IN DIFFUSE MIDLINE GLIOMA PATIENTS AHEAD OF THE SOCIETY OF NEURO-ONCOLOGY 2023 ANNUAL MEETING
- SYDNEY , Nov. 15, 2023 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, is pleased to announce that the Society of Neuro-Oncology 2023 Annual Meeting late breaking abstract entitled "PNOC022: a combination therapy trial using an adaptive platform design for patients with diffuse midline gliomas (DMGs) at initial diagnosis, post-radiation therapy and at time of therapy" was released by the conference organizers on 10 November 2023. The preliminary results from a single cohort in this Pacific Pediatric Neuro-Oncology Consortium (PNOC) sponsored cooperative group clinical study will be presented on Sunday, 19 November 2023 in Vancouver, Canada.
- 11/15/2023
|
KAZIA ANNOUNCES PUBLICATION IN MOLECULAR CANCER THERAPEUTICS HIGHLIGHTING PAXALISIB PRECLINICAL DATA IN MELANOMA
- SYDNEY , Nov. 10, 2023 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce the publication in Molecular Cancer Therapeutics highlighting paxalisib preclinical data stemming from the research collaboration with the Huntsman Cancer Institute at the University of Utah in Salt Lake City, UT. The paper by Dr Gennie Parkman and colleagues, working in the laboratory of Professor Sheri Holmen, has shown paxalisib to be active in vitro and in vivo against preclinical models of metastatic melanoma, the most aggressive form of skin cancer.
- 11/10/2023
|
KAZIA THERAPEUTICS PROVIDES PRELIMINARY UPDATE FROM ONGOING PHASE 2 STUDY OF PAXALISIB IN PRIMARY CNS LYMPHOMA
- SYDNEY , Nov. 1, 2023 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to provide a preliminary update from the ongoing investigator-initiated Phase 2 clinical trial (NCT04906096) evaluating paxalisib as monotherapy treatment in patients with relapsed/refractory primary central nervous system lymphoma (r/r PCNSL). This is an open-label, Phase 2 clinical trial, led by Dr. Lakshmi Nayak MD, of the Dana-Farber Cancer Institute in Boston, MA.
- 11/01/2023
|
KAZIA THERAPEUTICS ANNOUNCES CLINICAL DATA AT ESMO 2023 FROM ONGOING PHASE 1 EVT801 STUDY
- SYDNEY , Oct. 23, 2023 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, announces that selected clinical data from the company's ongoing Phase 1 clinical trial evaluating EVT801 in patients with advanced solid tumours was presented at the European Society of Medical Oncology Congress 2023 (ESMO 2023) on Saturday, 21 October 2023. Professor Carlos A Gomez-Roca, (IUCT-Oncopole, Toulouse France) presented data from a correlation analysis of tumour biopsies from six (6) enrolled patients with high grade serous ovarian cancer (HGS-OC).
- 10/23/2023
|
Kazia announces voluntary delisting from ASX
- SYDNEY , Oct. 11, 2023 /PRNewswire/ -- Kazia Therapeutics Limited (ASX:KZA, NASDAQ:KZIA) (Kazia or the Company), an oncology-focused drug development company, announces its intention to de-list from the Australian Securities Exchange (ASX). Delisting Kazia advises that it has submitted a formal application to the ASX to be removed from the official list of the ASX (Official List) in accordance with ASX Listing Rule 17.11 (Delist or the Delisting).
- 10/11/2023
|
KAZIA THERAPEUTICS ANNOUNCES PRESENTATIONS AT UPCOMING SCIENTIFIC MEETINGS
- SYDNEY , Oct. 5, 2023 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to provide an update regarding upcoming data presentations at two international scientific meetings, European Society for Medical Oncology (ESMO) Congress 2023 and Society for Neuro-Oncology (SNO) Annual Meeting. The presentations will highlight data for both investigational clinical drugs, EVT801 and Paxalisib.
- 10/05/2023
|
KAZIA THERAPEUTICS ANNOUNCES ACCEPTANCE OF LATE-BREAKING ABSTRACT AND ORAL PRESENTATION OF PNOC022 CLINICAL DATA AT 2023 SOCIETY FOR NEURO-ONCOLOGY ANNUAL MEETING
- SYDNEY , Sept. 29, 2023 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that data from an ongoing Phase II study (PNOC022, NCT05009992) of paxalisib, an investigational drug for the treatment of diffuse intrinsic pontine glioma (DIPG) and other diffuse midline gliomas (DMGs), sponsored by the Pacific Pediatric Neuro-Oncology Consortium (PNOC), has been awarded a late breaking oral presentation at the 2023 Society for Neuro-Oncology (SNO) Annual Meeting.
- 09/29/2023
|
Why Is Kazia Therapeutics (KZIA) Stock Moving Today?
- Kazia Therapeutics (NASDAQ: KZIA ) stock is on the move Thursday after the company received fast-track designation for its paxalisib program. The FDA granted the drug fast-track designation as it's designed to treat solid tumor brain metastases harboring PI3K pathway mutations.
- 07/06/2023
|
KAZIA THERAPEUTICS TO PRESENT AT HC WAINWRIGHT 24th ANNUAL GLOBAL INVESTMENT CONFERENCE
- SYDNEY , Sept. 9, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that CEO, Dr James Garner, will be presenting at the upcoming 24th Annual Global Investment Conference, held in New York, NY, from 12 – 14 September 2022.
- 09/09/2022
|
KAZIA TO PRESENT FINAL DATA FROM PAXALISIB PHASE II STUDY IN GLIOBLASTOMA AT ESMO
- SYDNEY , Sept. 8, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, today announced that final data from its phase II study of paxalisib in patients with newly diagnosed glioblastoma will be the subject of an oral presentation at the upcoming annual congress of the European Society for Medical Oncology (ESMO), which will be held in person from 9-13 September 2022 in Paris, France.
- 09/08/2022
|
Kazia Therapeutics (KZIA) Stock Soars on FDA Designation
- Kazia Therapeutics (KZIA) stock is taking off on Wednesday following an update from the FDA on its pediatric cancer treatment. The post Kazia Therapeutics (KZIA) Stock Soars on FDA Designation appeared first on InvestorPlace.
- 07/06/2022
|
KAZIA THERAPEUTICS TO PRESENT AT UPCOMING INVESTOR CONFERENCES HOSTED BY HC WAINWRIGHT AND LD MICRO
- SYDNEY , May 23, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that CEO, Dr James Garner, will be presenting at two upcoming investor conferences. Dr Garner will present on behalf of Kazia at the HC Wainwright Global Investment Conference, to be held in person and virtually in Miami, FL, from 23-26 May 2022.
- 05/23/2022
|
KAZIA TO PRESENT FINAL DATA FROM PAXALISIB PHASE II STUDY IN GLIOBLASTOMA AT ASCO
- SYDNEY , April 29, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, today announced that final data from its phase II study of paxalisib in patients with newly diagnosed glioblastoma will be the subject of a poster presentation at the upcoming Annual Meeting of the American Society for Clinical Oncology (ASCO). The ASCO Annual Meeting will take place virtually and in person from 3-7 June 2022 and will be held in Chicago, IL.
- 04/29/2022
|
Kazia Therapeutics (KZIA): Karen Krumeich Named As CFO
- Kazia Therapeutics Ltd (NASDAQ: KZIA) announced it has appointed Karen Krumeich as Chief Financial Officer. These are the details.
- 12/13/2021
|
Kazia Therapeutics appoints US-based CFO to assist global market expansion
- Kazia Therapeutics Ltd (ASX:KZA, NASDAQ:KZIA) has appointed Karen Krumeich as chief financial officer to focus on building and maintaining relationships with US investors, preparing the company for future expansion and raising the profile of Kazia in global markets. KZA's lead program is paxalisib, a brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, which is being developed to treat glioblastoma, the most common and most aggressive form of primary brain cancer in adults.
- 12/12/2021
|
Kazia Therapeutics releases positive final data from Phase 2 trial of glioblastoma treatment paxalisib, shares up
- Kazia Therapeutics Ltd (ASX:KZA, NASDAQ:KZIA), a cancer-focused drug development company based in Sydney, has released final data from its Phase 2 clinical study of the drug paxalisib – a first-line therapy in patients with glioblastoma. The company reports that these results confirm the asset's previously reported safety and efficacy markers, and the company has high hopes that this signals a breakthrough in the treatment of a complex disease of “high unmet need".
- 12/02/2021
|
Kazia Therapeutics expands further in North America with Toronto glioblastoma study
- Kazia Therapeutics Ltd (ASX:KZA, NASDAQ:KZIA)'s cancer drug, paxalisib, which targets glioblastoma, will now reach patients in Canada through a new study at Sunnybrook Health Sciences Centre in Toronto, Ontario. The company's flagship drug, paxalisib, is a candidate in GBM AGILE, a multi-drug platform study designed to identify promising new therapies for glioblastoma.
- 11/28/2021
|
Kazia Therapeutics appoints former Cellectar Biosciences chief medical officer John Friend as new CMO
- Kazia Therapeutics Ltd (ASX:KZA, NASDAQ:KZIA) has appointed John Friend MD, the former chief medical officer (CMO) at Cellectar Biosciences (NASDAQ:CLRB), Inc as its new CMO. Dr Friend will be responsible for overseeing the development and commercialization of Kazia's pipeline drug candidates, and collaborate with clinicians and scientists to advance the company's research programs.
- 11/14/2021
|
Kazia Therapeutics welcomes start of PNOC study in childhood brain cancer, first patient enrolled
- Kazia Therapeutics Ltd (ASX:KZA, NASDAQ:KZIA)'s investigational drug paxalisib is playing a role in PNOC022, a multi-drug phase II study in DIPG and diffuse midline gliomas, that has been initiated at the University of California, San Francisco, with the first patient enrolled to the study. Diffuse intrinsic pontine glioma (DIPG) is the most common of a group of childhood brain cancers known as diffuse midline gliomas (DMGs).
- 11/10/2021
|
Kazia Therapeutics enrols first patient to phase I clinical trial of EVT801 cancer therapy
- Kazia Therapeutics Ltd (ASX:KZA, NASDAQ:KZIA) has officially enrolled its first patient in its investigational cancer therapy trial. The oncology-focused drug development company licensed the cancer therapy, known as EVT801, from German biotech Evotec AG in April 2021.
- 11/03/2021
|
Kazia Therapeutics gets boost with ‘buy' call from Maxim Group and valuation upgrade from Edison
- Kazia Therapeutics Ltd (ASX:KZA, NASDAQ:KZIA) has received the nod from two research houses, with the Maxim Group LLC initiating coverage with a ‘buy' recommendation and Edison increasing its valuation to A$2.83 from A$2.68 per basic share. The Maxim Group has also put a 12-month target price of US$18 per American Depository Share (ADS), which is also listed on NASDAQ.
- 10/28/2021
|
Kazia Therapeutics' paxalisib program data garners increased target share price of A$2.83 from Edison
- Kazia Therapeutics Ltd has received an increased target price share from Edison Group, rising to A$2.83 from A$2.68 a share following the release of interim data for its 30-patient Phase II trial of paxalisib in newly diagnosed glioblastoma multiforme (GBM) patients. Final data from the trial as well as initial data for paxalisib in the treatment of brain metastases (BMs) is expected before the end of this year.
- 10/14/2021
|
Kazia Therapeutics to Present at LD Micro Main Event
- SYDNEY, Oct. 6, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that CEO, Dr James Garner, will be presenting at the LD Micro Main Event, to be held virtually and in person from 12-14 October 2021. Since 2008, the LD Micro Main Event has established itself as one of the leading conferences for small-cap companies across a wide range of sectors.
- 10/06/2021
|
Kazia Therapeutics to Present at HC Wainwright 23rd Annual Global Investment Conference
- SYDNEY, Sept. 10, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that CEO, Dr James Garner, will be presenting at the HC Wainwright 23rd Annual Global Investment Conference, to be held virtually from 13-15 September 2021.
- 09/10/2021
|
Kazia Therapeutics receives full regulatory approval for EVT801 phase 1 study
- Kazia Therapeutics Ltd has received full regulatory approval for its planned phase 1 study for EVT801 from L'Agence Nationale de Sécurité du Médicament et des Produits de Santé (ANSM), the French regulatory agency. Kazia, an oncology-focused drug development company, licensed EVT801 from Evotec SE, an international drug discovery alliance and development partnership company, in April 2021.
- 09/01/2021
|
Kazia Therapeutics directors support oncology-focused drug strategy with on-market purchases
- Kazia Therapeutics Ltd directors Dr James Garner and Iain Ross have shown their faith in the company's oncology-focused drug development strategy by acquiring shares on-market. Dr Garner, who is chief executive officer and an executive director, acquired 20,000 shares in two lots of 10,000 for total consideration of around $27,500 on August 27, 2021.
- 08/30/2021
|
Kazia Therapeutics has 'busy and productive' June quarter with important readouts slated for second half
- Kazia Therapeutics Ltd has had a “busy and productive” June quarter as it makes great strides with the paxalisib clinical program, including the launch of two new studies. The oncology-focused drug development company is also expecting a number of important read-outs targeted for the second half of the year.
- 07/30/2021
|
Kazia Calls for Increased Focus on Brain Cancer Research this GBM Awareness Day
- SYDNEY, July 21, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), a leading drug development company in the field of brain cancer, today recognizes Glioblastoma (GBM) Awareness Day and calls for a greater focus on research from industry, academia, and government in order to better treat the disease. GBM is the most common and most aggressive form of primary brain cancer, and it is expected that approximately 13,000 Americans will receive a GBM diagnosis in 2021.
- 07/21/2021
|
Kazia Provides Progress Update on Paxalisib and EVT801 Clinical Programs
- SYDNEY , June 30, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to provide an update on recent progress with its two pipeline assets, paxalisib and EVT801. Key Points GBM AGILE pivotal study of paxalisib is recruiting ahead of expectations, with almost 25 sites now open to the paxalisib arm.
- 06/30/2021
|
Kazia Therapeutics makes strong progress with clinical programs for paxalisib and EVT801
- Kazia Therapeutics Ltd (ASX:KZA) (NASDAQ:KZIA) has made strong progress in the first half of 2021 with its oncology-focused drug development program, including the pipeline assets of paxalisib and EVT801. The GBM AGILE pivotal study of paxalisib is recruiting ahead of expectations, with almost 25 sites now open to the paxalisib arm in the United States across several prestigious centres.
- 06/30/2021
|
Kazia Therapeutics lands key manufacturing patents for paxalisib in US and India
- Kazia Therapeutics Ltd (ASX:KZA) (NASDAQ:KZIA) has secured manufacturing patents for its paxalisib cancer treatment candidate in key territories, extending its patent protection out until 2036. The oncology-focused drug development company has been awarded manufacturing patents in the US and India, while a similar patent has progressed in Australia and is on track to be granted in the coming quarter.
- 06/23/2021
|
Kazia Enters Clinical Collaboration With Cornell University for Phase II Clinical Study Using Paxalisib in Combination With Ketogenic Diet for Glioblastoma
- SYDNEY, June 15, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that it has entered a collaboration with the Joan & Sanford I Weill Medical College of Cornell University in the United States, to launch a phase II clinical study investigating the use of Kazia's investigational new drug, paxalisib, in combination with ketogenesis, for glioblastoma. Key Points Research by Professor Lew Cantley, who discovered the PI3K pathway, suggests that ketogenesis may enhance the activity of PI3K inhibitors in glioblastoma, with impressive preclinical data previously published in Nature Ketogenesis represents an alternative biochemical mechanism in which the body is fueled by fats and proteins rather than by glucose; it occurs in states such as starvation, and also in response to a 'ketogenic diet' Data from this study has the potential to significantly enhance the activity of paxalisib in glioblastoma, and to minimize certain side effects, including hyperglycemia (high blood sugar) Dr Howard Fine, founding Director of the Brain Tumor Center at New York-Presbyterian Weill Cornell Medical Center, will serve as Principal Investigator; Professor Cantley will be a scientific advisor to the study Kazia will provide support including study drug and a financial grant Dr Fine, Principal Investigator to the study, commented, "glioblastoma remains an immensely challenging disease, and we need the most potent array of tools at our disposal in order to treat it.
- 06/15/2021
|
Kazia Therapeutics to collaborate with Cornell University for new paxalisib phase II clinical trial
- Kazia Therapeutics Ltd (ASX:KZA) (NASDAQ:KZIA) has teamed up with a medical college from Cornell University to launch a phase two clinical study investigating Kazia's investigational new drug paxalisib in combination with ketogenesis. Specifically, the study will evaluate Kazia's paxalisib candidate, in combination with ketogenesis, for treating an aggressive form of cancer known as glioblastoma.
- 06/14/2021
|
Study of Paxalisib in Primary CNS Lymphoma at Dana-Farber Cancer Institute Enrols First Patient
- SYDNEY, June 7, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that a phase II study of Kazia's investigational new drug, paxalisib, in primary CNS lymphoma has been initiated at Dana-Farber Cancer Institute, with the first patient successfully enrolled to the study. Key Points Lymphoma is a cancer of white blood cells.
- 06/07/2021
|
Kazia Therapeutics study of paxalisib in primary CNS Lymphoma at Dana-Farber enrols first patient
- Kazia Therapeutics Ltd's (ASX:KZA) (FRA:NV9M) (NASDAQ:KZIA) phase-II study of paxalisib in Primary CNS Lymphoma has been initiated at Dana-Farber Cancer Institute in Boston, Massachusetts, with the first patient enrolled to the study. Lymphoma is a cancer of white blood cells that occurs in the lymphatic system and can spread almost anywhere in the body while primary CNS lymphoma (PCNSL) occurs exclusively in the brain and central nervous system.
- 06/06/2021
|
Kazia Therapeutics directors demonstrate confidence in bio-tech strategy with on-market purchases
- Kazia Therapeutics Ltd (ASX:KZA) (NASDAQ:KZIA) (FRA:NV9M) directors have demonstrated confidence in the company's bio-tech strategy with on-market share purchases. Non-executive director Steven Coffey acquired 8,000 shares in an indirect interest on June 1 and 2, increasing his holding to 426,250 shares with another 8,015 held in a direct interest.
- 06/02/2021
|
Kazia Therapeutics directors demonstrate confidence in company with on-market purchases
- Kazia Therapeutics Ltd (ASX:KZA) (NASDAQ:KZIA) (FRA:NV9M) directors have demonstrated their confidence in the company's biotech strategy with on-market purchases. Non-executive director Steven Coffey acquired 7,250 shares at $1.40 per share in an indirect interest between April 30 and May 3, increasing the number of securities held in that interest to 418,250 shares with another 8,015 held in a direct interest.
- 05/04/2021
|
Kazia Therapeutics lands trifecta of licensing deals in March quarter, leaving it "a vastly stronger and more substantial business"
- Kazia Therapeutics Ltd (ASX:KZA) (NASDAQ:KZIA) (FRA:NV9M) has kicked off 2021 with a trifecta of March quarter licensing deals, leaving it "a vastly stronger and more substantial business", according to CEO Dr James Garner. During the quarter, the oncology-focused drug development company saw maiden revenue of A$5.3 million and its cash position increased to A$19.7 million by the end of March.
- 04/30/2021
|
Kazia Therapeutics' EVT801 deal secures price target of A$2.60 from Corporate Connect and BUY rating from HC Wainwright
- Kazia Therapeutics Ltd (ASX:KZA) (NASDAQ:KZIA) (FRA:NV9) recently announced an agreement with Evotec SE (FRA:EVT) to in-license the global rights to EVT801, a novel inhibitor of vascular endothelial growth factor receptor 3 (VEGFR3). Off the back of the deal, HC Wainwright & Co analysts Sean Lee, Swayampakula Ramakanth, Arthur He, Sean Kang have maintained the company's BUY rating and 12-month price target of US$17.00 per ADS.
- 04/25/2021
|
Kazia Therapeutics valuation lifts off the back of in-licensing of EVT901 drug: Edison Group
- Kazia Therapeutics Ltd's (ASX:KZA) (FRA:NV9) (NASDAQ:KZIA) valuation has increased to A$346 million or A$2.68 per share from A$301 million or A$2.32 per share following the company's in-licensing of EVT801, a novel small molecule inhibitor of VEGFR3, from Evotec SE (FRA:EVT) (OTCMKTS:EVTCY) A new research report from Edison Group analyst Nathaniel Calloway highlighted the expansion of the company's product pipeline to include EVT801 as a good strategic fit while paxalisib is in the clinic. He said: "Strategically, this is an important deal for Kazia, because it enables it to expand the pipeline to multiple drugs.
- 04/20/2021
|
Kazia Therapeutics licenses global rights to novel, first-in class, clinic-ready oncology drug candidate EVT801
- Kazia Therapeutics Ltd (ASX:KZA) (FRA:NV9) (NASDAQ:KZIA) has entered into a worldwide exclusive licensing agreement as well as a master services agreement with Evotec SE (FRA:EVT) – a leading European drug discovery and development company. The agreement was made for EVT801 – a small molecule, first-in class oncology drug candidate, for which Kazia expects to launch a phase-I clinical trial in 2021.
- 04/19/2021
|
KZIA Stock: 3% Increase Pre-Market Explanation
- The stock price of Kazia Therapeutics Ltd (NASDAQ: KZIA) increased by 3% pre-market. This is why it happened.
- 04/19/2021
|
Kazia Therapeutics halted with potential in-licensing transaction announcement pending
- Kazia Therapeutics Ltd (ASX:KZA) (NASDAQ:KZIA) (FRA:NV9) is in a trading halt pending an announcement in regard to a potential in-licensing transaction. In its application to the ASX for the halt, Kazia stated the announcement was pending the conclusion of negotiations.
- 04/16/2021
|
Kazia Therapeutics licensing deals result in A+ rating and $2.60 price target from Corporate Connect
- Kazia Therapeutics Ltd (ASX:KZA) (NASDAQ:KZIA) (FRA:NV9) has secured an increased price target from A$2.25 to A$2.60 a share by Corporate Connect analyst Marc Sinatra on the back of two recent licensing deals. The company signed an licensing deal with China-based Simcere Pharmaceutical Group Limited (HKSE:2906) for paxalisib in Greater China and earlier in March with Oasmia Pharmaceutical AB (STO: OASM) (OTCMKTS:OASMY) for worldwide rights to Cantrixil.
- 04/14/2021
|
Kazia Therapeutics to present pharmacokinetic data from Paxalisib Phase II study at prestigious AACR annual meeting
- Kazia Therapeutics Ltd (ASX:KZA) (NASDAQ:KZIA) (FRA:NV9) will share new data from its ongoing phase II study of paxalisib in glioblastoma in a poster presentation at the prestigious American Association of Cancer Research (AACR) Annual Meeting being held virtually from April 10-15 and from May 17-21, 2021. The new pharmacokinetic (PK) data shows how long paxalisib remains in the human body and strongly supports 60-milligram once-daily dosing, confirming the company's planned administration schedule for commercial launch.
- 04/08/2021
|
Kazia Therapeutics (KZIA): Paxalisib Chinese Rights Licensed
- LONDON, UK / ACCESSWIRE / March 30, 2021 / Kazia (NASDAQ:KZIA) has announced it has signed an agreement for the Greater China rights to paxalisib with Simcere Pharmaceuticals. The deal includes an US$11m upfront (US$7m in cash, and US$4m in an equity investment), up to US$281m in milestone payments and royalties in the mid-teens.
- 03/30/2021
|
Kazia Therapeutics enters one of world's largest pharma markets through Chinese licensing deal for paxalisib with Simcere Pharmaceutical
- Kazia Therapeutics Ltd (ASX:KZA) (NASDAQ:KZIA) (FRA:NV9) has entered into a licensing agreement with Simcere Pharmaceutical Group Ltd (HKSE:2096) to develop and commercialise Kazia's investigational new drug, paxalisib, in Greater China. Simcere will assume responsibility for the development, registration and commercialisation of paxalisib in Greater China - which includes mainland China, Hong Kong, Macau, and Taiwan.
- 03/29/2021
|
KZIA Stock Price Increased Over 20% Pre-Market: Why It Happened
- The stock price of Kazia Therapeutics Ltd (NASDAQ: KZIA) increased by over 20% pre-market. This is why it happened.
- 03/29/2021
|
Kazia Therapeutics Stock Is Trading Higher On Paxalisib Licensing Agreement In Greater China
- Kazia Therapeutics Ltd (NASDAQ: KZIA) has entered into a licensing agreement with Simcere Pharmaceutical Group Ltd to develop and commercialize Kazia's investigational new drug, paxalisib, in Greater China. Kazia retains rights to the development and commercialization of paxalisib in all other territories and will continue to drive forward the GBM AGILE pivotal study as planned, including in China.
- 03/29/2021
|
Kazia Therapeutics in trading halt with regional licensing transaction news pending
- Kazia Therapeutics Ltd (ASX:KZA) (NASDAQ:KZIA) (FRA:NV9) has been granted a trading halt by the ASX pending the release of an announcement regarding a regional licensing transaction. The halt will be in place until the start of regular trading on Tuesday, March 30, or when an announcement is released to the market, whichever occurs earliest.
- 03/25/2021
|
Kazia Therapeutics CEO and MD highlights 2021 progress with focus on providing treatment for diagnosed glioblastoma
- Kazia Therapeutics Ltd's (ASX:KZA) (NASDAQ:KZIA) (FRA:NV9) chief executive officer and MD James Garner has highlighted the company's progress over the course of the year to date in its March newsletter, stating that the focus remains on preparing a new drug application (ND) to the US FDA. While he said the oncology-focused biotechnology company had witnessed a ‘critical watershed' in its development with the transition of paxalisib into a pivotal study for registration, Kazia was continuing to collect additional data, refining manufacturing and increasing interactions with FDA.
- 03/18/2021
|
Kazia Therapeutics Licenses Cantrixil To Oasmia Pharmaceutical For Ovarian Cancer
- Kazia Therapeutics Ltd (NASDAQ: KZIA) has entered an exclusive worldwide licensing agreement with Oasmia Pharmaceutical AB (OTCMKTS: OASMY) for Cantrixil under development the treatment of ovarian cancer. The agreement will see Sweden-based Oasmia assume exclusive worldwide rights to develop and commercialize Cantrixil for all indications, with an initial focus on ovarian cancer.
- 03/01/2021
|
Kazia Therapeutics achieves key half-year milestones and ends period with cash balance of $19.4 million
- Kazia Therapeutics Ltd (ASX:KZA) (NASDAQ:KZIA) (FRA:NV9) made substantial progress and achieved key milestones in the half-year ending December 31, 2020, ending the period with a cash balance of A$19.4 million and net assets of A$31.7 million. Chairman Iain Ross stated in the half-year report that in line with Kazia's ongoing focus on cost efficiency, more than 90% of its expenditure in this period was invested directly in R&D programs.
- 02/24/2021
|
US FDA Awards Fast Track Designation (FTD) to Paxalisib for Glioblastoma
- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that the United States Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to Kazia's paxalisib (formerly GDC-0084) for the treatment of glioblastoma, the most common and most aggressive form of primary brain cancer.
- 08/20/2020
|
US FDA Grants Rare Pediatric Disease Designation (RPDD) to Paxalisib for DIPG
- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that the United States Food and Drug Administration (FDA) has awarded Rare Pediatric Disease Designation (RPDD) to Kazia's paxalisib (formerly GDC-0084) for the treatment of Diffuse Intrinsic Pontine Glioma (DIPG), a rare and highly-aggressive childhood brain cancer.
- 08/07/2020
|
Kazia Presents Further Paxalisib and Cantrixil Data at AACR, Reinforcing Positive Efficacy Signals for both Drugs
- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to share poster presentations of interim data from the ongoing phase II study of paxalisib (formerly GDC-0084) in glioblastoma, the most common and most aggressive form of primary brain cancer, and from the phase I study of Cantrixil in ovarian cancer.
- 06/22/2020
|
Kazia Presents Further Paxalisib and Cantrixil Data at AACR, Reinforcing Positive Efficacy Signals for both Drugs
- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to share poster presentations of interim data from the ongoing phase II study of paxalisib (formerly GDC-0084) in glioblastoma, the most common and most aggressive form of primary brain cancer, and from the phase I study of Cantrixil in ovarian cancer.
- 06/22/2020
|
Kazia Presents Interim Paxalisib Phase II Data at ASCO Showing Positive Overall Survival Signal
- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to share a poster presentation of interim data from the ongoing phase II study of paxalisib (formerly GDC-0084) in glioblastoma, the most common and most aggressive form of primary brain cancer. Top-line data from this interim analysis was previously announced to ASX on 7 April 2020.
- 06/01/2020
|
Iain Ross Is The Independent Chairman of the Board of Kazia Therapeutics Limited (ASX:KZA) And They Just Picked Up 19% More Shares
- Even if it's not a huge purchase, we think it was good to see that Iain Ross, the Independent Chairman of the Board of...
- 05/29/2020
|
Did You Manage To Avoid Kazia Therapeutics' (ASX:KZA) Devastating 86% Share Price Drop?
- Long term investing works well, but it doesn't always work for each individual stock. It hits us in the gut when we...
- 05/25/2020
|
NLY, NRZ among premarket gainers
- Ellington Financial (NYSE:EFC) +54% as book value holds up.New York Mortgage Trust (NASDAQ:NYMT) +39% on updating on financing, portfolio.Myomo (NYSEMKT:MYO) +26% on accelerating growth in pipeline an
- 04/08/2020
|
Kazia's Paxalisib Shows Positive Overall Survival Signal in Phase II Glioblastoma Study
- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to share positive interim data from its ongoing phase II study of paxalisib (formerly GDC-0084) in glioblastoma, the most common and most aggressive form of primary brain cancer.
- 04/07/2020
|
Is Kazia Therapeutics Limited's (ASX:KZA) CEO Paid At A Competitive Rate?
- James Garner became the CEO of Kazia Therapeutics Limited (ASX:KZA) in 2016. First, this article will compare CEO...
- 02/24/2020
|
Edison issues ADR update on Kazia Therapeutics (KZIA)
- LONDON, UK / ACCESSWIRE / January 13, 2020 / Kazia Therapeutics (NASDAQ:KZIA) has announced that GDC-0084, its promising glioblastoma drug, will join (subject to definitive agreement) the pivotal GBM AGILE ...
- 01/13/2020
|
Kazia Initiates Preparatory Activities to Bring GDC-0084 into GBM AGILE, an International Phase II / III Study in Glioblastoma
- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that it's lead program, GDC-0084, has been selected to join GBM AGILE, an international, academic-led, multi-drug adaptive phase II / III study in glioblastoma. It is expected that data from GBM AGILE will be used to seek marketing approval for GDC-0084 from FDA and other regulatory agencies.
- 12/11/2019
|
Edison issues ADR outlook on Kazia Therapeutics (KZIA)
- LONDON, UK / ACCESSWIRE / December 2, 2019 / Kazia Therapeutics (NASDAQ:KZIA) has presented very encouraging initial efficacy data from the dose-ranging stage of its current Phase II trial. The data are ...
- 12/02/2019
|
If You Had Bought Kazia Therapeutics (ASX:KZA) Shares A Year Ago You'd Have Made 60%
- The simplest way to invest in stocks is to buy exchange traded funds. But if you pick the right individual stocks, you...
- 11/28/2019
|
Positive Interim Efficacy Data from GDC-0084 Phase II Study in Glioblastoma Released at SNO Conference
- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to share with investors interim data from its ongoing phase II study of GDC-0084 in glioblastoma, the most common and most aggressive form of primary brain cancer. This data is the subject of a poster presentation at the annual meeting of the Society for Neuro-Oncology (SNO), held in Phoenix, AZ from 20 - 24 November 2019.
- 11/25/2019
|
Kazia Raises A$4.0 Million to Progress R&D Programs
- NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce the completion of a placement of ten million new fully paid ordinary shares in the Company (New Shares) to institutional, professional, and sophisticated investors in Australia and internationally, at a price of A$0.40 per New Share (Institutional Placement). The Institutional Placement will raise A$4.0 million (exclusive of costs).
- 10/28/2019
|
Kazia wins ANZLF Trans-Tasman Innovation & Growth Award and reports new data from clinical trial in childhood brain cancer
- SYDNEY, Sept. 13, 2019 /PRNewswire/ -- Australian oncology-focused biotech company Kazia Therapeutics Ltd (ASX: KZA, NASDAQ: KZIA) is pleased to announce that it has been named as a winner in the 2019 ANZLF Trans-Tasman Innovation & Growth Awards. The Awards celebrate the innovation, growth and impact of emerging businesses in Australia and New Zealand and were presented by New Zealand Prime Minister Jacinda Arden at a ceremony in Auckland on September 12. Kazia was recognised for being an innovative, product-focused and agile company and the award also reflected its significant progress in the clinical testing of its lead candidate, GDC-0084, which is being developed to treat glioblastoma, the most common and most aggressive form of primary brain cancer in adults, as well as other forms of brain cancer.
- 09/13/2019
|
St Jude Study of GDC-0084 in DIPG Successfully Completes First Stage; Second Part of Study Now Underway
- NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that St Jude Children's Research Hospital has successfully completed the first stage of its ongoing phase I study of Kazia's investigational new drug, GDC-0084 in diffuse intrinsic pontine glioma (DIPG) and other diffuse midline gliomas, which represent a group of childhood brain cancers with high unmet need. Dr. Christopher Tinkle, co-Lead Investigator on the study, commented, "to date, thirteen patients have received GDC-0084 in our study.
- 09/12/2019
|
Kazia to test GDC-0084 with Radiotherapy in Phase I Clinical Trial at Leading US Cancer Center
- NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that Memorial Sloan Kettering Cancer Center (MSK) in New York, NY will investigate the potential use of Kazia's investigational new drug, GDC-0084, in combination with radiotherapy in a phase I clinical trial for cancer that has spread to the brain (brain metastases and leptomeningeal metastases). This research will explore a new use of GDC-0084 and will run concurrently with other ongoing studies in different forms of brain cancer.
- 07/22/2019
|
Kazia calls for greater awareness of the deadliest brain cancer in the US
- SYDNEY , July 17, 2019 /PRNewswire/ -- T his Glioblastoma Awareness Day, Australian oncology-focused biotech company, Kazia Therapeutics Ltd (ASX: KZA, NASDAQ: KZIA), calls for greater awareness of the ...
- 07/17/2019
|
